The University of Manchester, Salford Royal Hospital, Dermatology Research Centre, Manchester Academic Health Science Centre, Manchester, UK.
Expert Opin Pharmacother. 2013 Apr;14(6):767-74. doi: 10.1517/14656566.2013.775247. Epub 2013 Mar 6.
Pimecrolimus is a calcineurin inhibitor which has a role in the treatment of psoriasis. However, it remains an off-license treatment, despite its potential use in patients with treatment-resistant psoriasis or in those who have had multiple adverse effects to other therapies.
This review covers the efficacy and role of both topical and oral Pimecrolimus in the management of psoriasis and compares them to other available treatments. The paper provides a comprehensive review of the literature on topical and oral Pimecrolimus and its utility in the treatment of patients with psoriasis following literature searches via PubMed and Embase.
Topical Pimecrolimus is an effective, off-license treatment option particularly for facial and intertriginous psoriasis. Oral Pimecrolimus shows great promise as an alternative systemic treatment option, but Phase III trials are required before further recommendations can be made.
吡美莫司是一种钙调磷酸酶抑制剂，在治疗银屑病方面具有一定作用。然而，尽管吡美莫司可能对治疗抵抗性银屑病患者或对其他治疗有多种不良反应的患者有效，但它仍然是一种超适应证治疗。
本文综述了局部和口服吡美莫司在银屑病治疗中的疗效和作用，并将其与其他可用治疗方法进行了比较。本文通过对 PubMed 和 Embase 进行文献检索，对局部和口服吡美莫司及其在治疗银屑病患者中的应用进行了全面综述。
局部吡美莫司是一种有效的、超适应证的治疗选择，特别是对面部和皱褶部银屑病。口服吡美莫司作为一种替代全身治疗的选择具有很大的潜力，但需要进行 III 期临床试验，然后才能提出进一步的建议。
